EXACT SCIENCES (EXAS) Company Report

Monteverde & Associates PC is investigating Exact Sciences Corporation (NASDAQ:EXAS) regarding its proposed sale to Abbott Laboratories.
Under the terms of the transaction, Exact Sciences shareholders are expected to receive $105.00 per common share.
The law firm is investigating whether this proposed deal is fair to shareholders.

7 days ago

Press Release

Exact Sciences to be Acquired by Abbott Laboratories

EXAS

M&A

Takeover Bid

Revenue Acceleration/Inflection

Abbott Laboratories announced a definitive agreement to acquire Exact Sciences Corporation on November 20, 2025.
Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.
The transaction, which includes Abbott absorbing Exact Sciences' estimated $1.8 billion of net debt, is expected to close in the second quarter of 2026.
Exact Sciences is projected to generate more than $3 billion in revenue in 2025, and the acquisition is expected to be immediately accretive to Abbott's revenue growth and gross margin.

Nov 20, 2025, 1:02 PM

8-K

Exact Sciences Announces HSR Waiting Period Expiration and Updated 2025 Guidance

EXAS

Guidance Update

New Projects/Investments

Exact Sciences announced the expiration of the Hart-Scott-Rodino (HSR) waiting period for its license agreement with Freenome.
This agreement grants Exact Sciences exclusive rights in the United States to Freenome's blood-based colorectal cancer (CRC) screening tests, expanding Exact Science’s leadership in cancer screening.
The exclusivity of the license remains subject to Freenome's test receiving first-line FDA approval.
The company has updated its full year 2025 adjusted EBITDA guidance to reflect an initial $75 million cash payment for the licensing agreement, revising the range from $470 - $480 million to $395 - $405 million.

Nov 10, 2025, 12:00 PM

Press Release

Exact Sciences Announces Positive Clinical Trial Results for Oncoguard Liver Test

EXAS

Product Launch

New Projects/Investments

Exact Sciences announced breakthrough results from the ALTUS study for its Oncoguard® Liver blood test, demonstrating superior early detection of hepatocellular carcinoma (HCC).
The Oncoguard® Liver blood test showed seven times greater sensitivity for very early-stage HCC compared to standard ultrasound surveillance.
In the ALTUS study, the Oncoguard Liver test achieved 64% sensitivity for very early-stage HCC versus 9% for ultrasound, and 77% sensitivity for early-stage HCC versus 36% for ultrasound.
The test also demonstrated a specificity of 82%.
These findings will be presented at The Liver Meeting® on November 11, 2025.

Nov 7, 2025, 1:00 PM

Press Release

Exact Sciences Announces Q3 2025 Results, Raises Full-Year Guidance, and Launches Cancerguard

EXAS

Earnings

Guidance Update

Product Launch

Exact Sciences reported record total third quarter 2025 revenue of $851 million, marking a 20% increase on a reported and core revenue basis, with Screening revenue at $666 million and Precision Oncology revenue at $184 million.
The company raised its full-year 2025 revenue and adjusted EBITDA guidance midpoints by $78 million and $10 million, respectively, now projecting total revenue between $3.220 billion and $3.235 billion and adjusted EBITDA between $470 million and $480 million.
For Q3 2025, Exact Sciences generated record cash from operations of $220 million and free cash flow of $190 million, representing increases of 59% and 69% respectively.
The company's net loss for Q3 2025 was $20 million, or $0.10 per share, an improvement of $19 million and $0.10 per share compared to the same period in 2024.
In September 2025, Exact Sciences launched Cancerguard®, its multi-cancer early detection test, for patients in the United States.

Nov 3, 2025, 9:07 PM

8-K

Exact Sciences Announces Third Quarter 2025 Results

EXAS

Earnings

Guidance Update

Product Launch

Exact Sciences reported record total third quarter 2025 revenue of $851 million, marking a 20% increase on both a reported and core revenue basis compared to the same period in 2024.
The company's net loss was $20 million, or $0.10 per share, an improvement of $19 million and $0.10 per share, respectively, while Adjusted EBITDA grew 37% to $135 million.
Exact Sciences raised its full-year 2025 revenue guidance midpoint by $78 million to $3.220 - $3.235 billion and its adjusted EBITDA guidance midpoint by $10 million to $470 - $480 million.
The company launched Cancerguard, its multi-cancer early detection test, for patients in the United States in September 2025.
Exact Sciences generated record cash from operations of $220 million and free cash flow of $190 million, with cash, cash equivalents, and marketable securities totaling $1.00 billion at quarter-end.

Nov 3, 2025, 9:05 PM

Press Release

Exact Sciences Presents New Cologuard Data at ACG 2025

EXAS

Product Launch

New Projects/Investments

Exact Sciences presented new data at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2025, demonstrating how its Cologuard test improves adherence and closes colorectal cancer screening gaps.
Research highlighted higher completion rates for mt-sDNA testing and the positive impact of patient navigation in expanding access to underserved and older populations.
A study comparing next-generation mt-sDNA to FIT screening projected that mt-sDNA screened more than twice as many patients (713,000 vs 318,000) and detected 5.5x more advanced precancerous lesions and 3.7x more colorectal cancer cases, while reducing treatment costs by 3% and total costs by 2%.
The Cologuard and FDA-approved Cologuard Plus tests are first-line, noninvasive colorectal cancer screening options for average-risk adults aged 45 or older, with Cologuard having been used over 20 million times since 2014.

Oct 27, 2025, 11:00 AM

Press Release

Exact Sciences Announces Positive Study Results for Cologuard Plus

EXAS

Product Launch

New Projects/Investments

A new study published in the Journal of the National Cancer Institute found that Exact Sciences' Cologuard Plus™ provides the most life-years gained with the fewest colonoscopies among colorectal cancer screening strategies.
The study, which used methodologies adopted by the United States Preventive Services Task Force (USPSTF), concluded that Cologuard Plus, a triennial next-generation multitarget stool DNA (mt-sDNA) test, was the only noninvasive screening option shown to be efficient at guideline-recommended intervals and age ranges.
Cologuard Plus offers high performance with a 95% sensitivity for CRC and 94% specificity in the U.S. screening age population, making it an important tool to improve colorectal cancer outcomes and preserve limited colonoscopy capacity. It is an FDA-approved first-line, noninvasive colorectal cancer screening option for average-risk adults aged 45 or older.

Oct 7, 2025, 10:59 AM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for EXACT SCIENCES.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Kevin Conroy say about margins?What are EXACT SCIENCES's strategic priorities?How is EXACT SCIENCES positioned vs competitors?How did EXACT SCIENCES do last quarter?

Let Fintool AI Agent track EXACT SCIENCES's earnings for you

Get instant analysis when filings drop